{"output": [["Viamet Pharmaceuticals", "ORG", "Announce", "NovaQuest Capital", "ORG"], ["Viamet Pharmaceuticals", "ORG", "Operate_In", "Research Triangle Park", "GPE"], ["NovaQuest Capital", "ORG", "Assume_Role", "Interim Chief Executive Officer", "TITLE"], ["VT-1161", "PRODUCT", "Complete", "Phase 2b clinical trials", "EVENT"], ["VT-1161", "PRODUCT", "Treat", "recurrent vulvovaginal candidiasis", "CONCEPT"], ["VT-1161", "PRODUCT", "Treat", "onychomycosis", "CONCEPT"], ["VT-1161", "PRODUCT", "Belong_To", "NovaQuest Capital", "ORG"], ["VT-1161", "PRODUCT", "Potent_Against", "Candida species", "SECTOR"], ["VT-1161", "PRODUCT", "Avoid", "side effects", "CONCEPT"], ["VT-1161", "PRODUCT", "Avoid", "drug-drug interactions", "CONCEPT"], ["RVVC", "CONCEPT", "Affect", "Approximately 5 to 8 percent of women", "ECON_INDICATOR"], ["Onychomycosis", "CONCEPT", "Affect", "Approximately 32 million individuals", "ECON_INDICATOR"], ["RVVC", "CONCEPT", "Lead_To", "Intense discomfort", "CONCEPT"], ["RVVC", "CONCEPT", "Lead_To", "Substantial negative impact on psychological well-being", "CONCEPT"], ["Onychomycosis", "CONCEPT", "Common_Infection", "Nail", "PRODUCT"], ["Onychomycosis", "CONCEPT", "Significant_Medical_Issue", "Diabetics", "PERSON"], ["Onychomycosis", "CONCEPT", "Significant_Medical_Issue", "Patients with compromised immune systems", "PERSON"], ["Onychomycosis", "CONCEPT", "Significant_Medical_Issue", "Patients with poor circulation of the lower extremities", "PERSON"]], "published": "2018-01-03T16:00:00.000+02:00"}